Literature DB >> 28418641

Classics in Chemical Neuroscience: Ketamine.

Marshall W Tyler1, Harmony B Yourish2, Dawn F Ionescu3, Stephen J Haggarty1.   

Abstract

Ketamine, a molecule of many faces, has contributed immeasurably to numerous realms of clinical practice and scientific inquiry. From anesthesia and analgesia to depression and schizophrenia, it continues to shed light on the molecular underpinnings of pain, consciousness, and the pathophysiology of neuropsychiatric disorders. In particular, research on ketamine's mechanism of action is providing new hope in the search for therapies for treatment-resistant depression and affords insights into disorders of glutamatergic dysfunction. In this Review, we will cover aspects of ketamine's synthesis, manufacturing, metabolism, pharmacology, approved and off-label indications, and adverse effects. We will also discuss the captivating history of this molecule, its influence on neuropsychiatry, and its potential to advance the fields of chemical neuroscience and neuropharmacology.

Entities:  

Keywords:  Ketamine; anesthesia; depression; history; pharmacology; schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28418641     DOI: 10.1021/acschemneuro.7b00074

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  19 in total

1.  BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder.

Authors:  Lawrence R Marcin; Jayakumar Warrier; Srinivasan Thangathirupathy; Jianliang Shi; George N Karageorge; Bradley C Pearce; Alicia Ng; Hyunsoo Park; James Kempson; Jianqing Li; Huiping Zhang; Arvind Mathur; Aliphedi B Reddy; G Nagaraju; Gopikishan Tonukunuru; Grandhi V R K M Gupta; Manjunatha Kamble; Raju Mannoori; Srinivas Cheruku; Srinivas Jogi; Jyoti Gulia; Tanmaya Bastia; Charulatha Sanmathi; Jayant Aher; Rajareddy Kallem; Bettadapura N Srikumar; Kumar Kuchibhotla Vijaya; Pattipati S Naidu; Mahesh Paschapur; Narasimharaju Kalidindi; Reeba Vikramadithyan; Manjunath Ramarao; Rex Denton; Thaddeus Molski; Eric Shields; Murali Subramanian; Xiaoliang Zhuo; Michelle Nophsker; Jean Simmermacher; Michael Sinz; Charlie Albright; Linda J Bristow; Imadul Islam; Joanne J Bronson; Richard E Olson; Dalton King; Lorin A Thompson; John E Macor
Journal:  ACS Med Chem Lett       Date:  2018-04-13       Impact factor: 4.345

2.  Spinal associative plasticity in depth: evidence from animal model.

Authors:  Francesco Asci
Journal:  J Physiol       Date:  2018-04-15       Impact factor: 5.182

3.  Ketamine sensitization: Influence of dose, environment, social isolation and treatment interval.

Authors:  Keith A Trujillo; Colleen Y Heller
Journal:  Behav Brain Res       Date:  2019-10-05       Impact factor: 3.332

4.  Screening of dopamine in living cells and animal model via graphene quantum dots anchored 3D macroporous nonenzymatic sensor.

Authors:  Kun Wang; Yige Li; Manlin Qi; Chunyan Li; Biao Dong; Lin Xu; Lin Wang
Journal:  Mikrochim Acta       Date:  2022-09-14       Impact factor: 6.408

5.  NMDA receptor ion channel activation detected in vivo with [18F]GE-179 PET after electrical stimulation of rat hippocampus.

Authors:  Ali K Vibholm; Anne M Landau; Arne Møller; Jan Jacobsen; Kim Vang; Ole L Munk; Dariusz Orlowski; Jens Ch Sørensen; David J Brooks
Journal:  J Cereb Blood Flow Metab       Date:  2020-09-22       Impact factor: 6.200

6.  In Vivo [18F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primates.

Authors:  Matthias Schoenberger; Frederick A Schroeder; Michael S Placzek; Randall L Carter; Bruce R Rosen; Jacob M Hooker; Christin Y Sander
Journal:  ACS Chem Neurosci       Date:  2017-11-14       Impact factor: 4.418

Review 7.  The DARK Side of Total Synthesis: Strategies and Tactics in Psychoactive Drug Production.

Authors:  Schuyler A Chambers; Jenna M DeSousa; Eric D Huseman; Steven D Townsend
Journal:  ACS Chem Neurosci       Date:  2018-02-01       Impact factor: 4.418

8.  Predictive performance of parent-metabolite population pharmacokinetic models of (S)-ketamine in healthy volunteers.

Authors:  M E Otto; K R Bergmann; G Jacobs; Michiel J van Esdonk
Journal:  Eur J Clin Pharmacol       Date:  2021-02-11       Impact factor: 2.953

Review 9.  Advances in novel molecular targets for antidepressants.

Authors:  Qingzhong Wang; Yogesh Dwivedi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-07-16       Impact factor: 5.067

10.  The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports.

Authors:  Camila Sanz; Federico Zamberlan; Earth Erowid; Fire Erowid; Enzo Tagliazucchi
Journal:  Front Neurosci       Date:  2018-01-22       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.